Clinical trials: Aspergillus Tracheobronchitis

Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis

Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

• No Longer Available
• Age: 18 years and older
• Expanded access

Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks.

Conditions

Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Aspergillus Tracheobronchitis

Trial name

NCT05897294

Testing

Voriconazole Inhalation Powder

Sponsor

TFF Pharmaceuticals, Inc.